Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MARIDEBART CAFRAGLUTIDE ON MORTALITY AND MORBIDITY IN PARTICIPANTS LIVING WITH HEART FAILURE WITH PRESERVED OR MILDLY REDUCED EJECTION FRACTION AND OBESITY (MARITIME-HF)

Intervention/treatment:
MARIDEBART CAFRAGLUTIDE (AMG 133)
Medical condition:
HEART FAILURE WITH PRESERVED EJECTION FRACTION
Protocol code:
20230227
Control number:
298444
Status:
Recruiting
Approved:
June 25, 2025
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT07037459
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 99 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Amgen Call Center
Role
CONTACT
Phone:
866-572-6436
Sponsor
AMGEN CANADA INC

Locations

Alberta

University of Alberta Hospital
Edmonton, Alberta, T6G 2B7
Recruiting

Manitoba

Cardio 1
Winnipeg, Manitoba, R3L 1Z5
Recruiting
St Boniface Hospital
Winnipeg, Manitoba, R2H 2A6
Recruiting

Ontario

Brampton Clinical Trials
Brampton, Ontario, L6Z 4N5
Recruiting
Cambridge Cardiac Care Centre
Cambridge, Ontario, N1R 6V6
Recruiting
CardioQuest Research Centre
Sarnia, Ontario, N7T 4P5
Recruiting
CPS Research
Waterloo, Ontario, N2T 0C1
Recruiting
Curans Heart Center
Thunder Bay, Ontario, P7B 5N3
Recruiting
Diabetes Heart Research Centre
Toronto, Ontario, M6G 1M2
Recruiting
Heart Health Institute Research Incorporated
Scarborough Village, Ontario, M1B 4Z8
Recruiting
Kawartha Cardiology Clinical Trials
Peterborough, Ontario, K9J 0B2
Recruiting
KMH Cardiology Centres Incorporated Hamilton
Stoney Creek, Ontario, L8J 3W2
Recruiting
North York Diagnostic and Cardiac Centre
North York, Ontario, M6B 3H7
Recruiting
Partners in Advanced Cardiac Evaluation
Newmarket, Ontario, L3Y 2P6
Recruiting
Saul Vizel Professional Medicine Corporation - Vizel Cardiac Research
Cambridge, Ontario, N1R 7R1
Recruiting
Winchester District Memorial Hospital
Winchester, Ontario, K0C 2K0
Recruiting
Womens College Hospital
Toronto, Ontario, M5S 1B2
Recruiting

Quebec

Diex Recherche Sherbrooke Est
Sherbrooke, Quebec, J1E 0N8
Recruiting
Diex Recherche Trois Rivieres
Trois-Rivières, Quebec, G9A 4P3
Recruiting
Ecogene-21
Chicoutimi, Quebec, G7H 7K9
Recruiting
Montreal Heart Institute
Montreal, Quebec, H1T 1C8
Recruiting
Did you find what you were looking for?